• Safe DNA Gel Stain: High-Sensitivity, Safer DNA and RNA Dete

  2026-08-06

  Safe DNA Gel Stain is a highly sensitive, less mutagenic alternative to ethidium bromide for DNA and RNA gel staining. It supports both blue-light and UV excitation, enhancing user safety and experimental reproducibility in molecular biology nucleic acid detection.

• Propranolol: Translational Leverage in Cardiovascular and CN

  2026-08-06

  This thought-leadership article bridges the mechanistic underpinnings of propranolol—a non-selective β-adrenergic receptor blocker—with actionable strategies for translational researchers. It contextualizes propranolol’s dual cardiovascular and neurobehavioral activities, outlines protocol parameters, evaluates its position in the experimental landscape, and articulates next-generation translational opportunities, all while integrating SEO best practices and rigorous evidence.

• EZ Cap™ OVA mRNA: Optimizing Immunogen Delivery & Expression

  2026-08-05

  EZ Cap™ OVA mRNA empowers immunology, gene expression, and vaccine research with high-purity, Cap 1-structured ovalbumin transcripts engineered for consistent delivery and reduced innate immune activation. This article translates the latest innovations in mRNA delivery—including mildronate-derived lipidoids—into actionable protocols and troubleshooting strategies for advanced immune response modeling.

• SAR131675: Potent, Selective VEGFR-3 Inhibitor for Lymphangi

  2026-08-05

  SAR131675 is a selective, ATP-competitive VEGFR-3 inhibitor with nanomolar potency and high kinase selectivity. It suppresses VEGFR-3-mediated lymphangiogenesis and angiogenesis, demonstrating antitumor efficacy in preclinical models. Despite promising results, development was discontinued due to adverse metabolic effects.

• Anti-HMGB1 Rabbit Monoclonal Antibody: Technical Guide (MA30

  2026-08-04

  The Anti-HMGB1 Rabbit Monoclonal Antibody (SKU MA3057) enables specific and reproducible detection of HMGB1 protein in human, mouse, and rat research samples using Western blot, immunohistochemistry, and flow cytometry. It is not validated for diagnostic, therapeutic, or medical applications and is best suited for chromatin-associated protein studies within controlled research environments.

• Artesunate as an Artemisinin Derivative in Cancer Workflows

  2026-08-04

  Artesunate is redefining in vitro cancer research as a high-purity artemisinin derivative, enabling robust cell death and proliferation assays. Its dual action as a ferroptosis inducer and AKT/mTOR pathway inhibitor streamlines experimental workflows, particularly in challenging small cell lung and esophageal squamous cell carcinoma models.

• Z-DEVD-FMK (SKU A1920): Reliable Caspase-3 Inhibitor for Apo

  2026-08-03

  This article offers an evidence-based, scenario-driven exploration of Z-DEVD-FMK (SKU A1920) for apoptosis and neuroprotection research. By addressing real laboratory challenges, it illustrates how Z-DEVD-FMK's validated protocol parameters, broad caspase inhibition, and reproducibility—supported by APExBIO—enhance reliability in cell viability and cytotoxicity workflows.

• SAR131675: Advanced VEGFR-3 Inhibitor Workflows & Troublesho

  2026-08-03

  SAR131675 unlocks precision targeting of VEGFR-3 in lymphangiogenesis, angiogenesis, and tumor models. This guide delivers actionable protocols, troubleshooting wisdom, and translational insights—driven by new evidence and APExBIO's trusted reliability.

• miR-1268a Controls CD36-Mediated Fatty Acid Metabolism in An

  2026-08-02

  This study uncovers a novel role for miR-1268a in regulating fatty acid metabolism through direct targeting of CD36 in human cardiomyocytes subjected to Angiotensin II-induced stress. The findings provide mechanistic insight into the metabolic remodeling characteristic of heart failure and highlight miR-1268a as a potential therapeutic target for metabolic intervention in cardiovascular disease.

• HAUS1 Expression and Immune Microenvironment in HCC Prognosi

  2026-08-01

  This study explores the prognostic value of HAUS1 expression in hepatocellular carcinoma (HCC) and its association with the tumor immune microenvironment. The findings highlight HAUS1 as a potential biomarker and therapeutic target, with implications for prognosis and immunotherapeutic strategy in HCC.

• Technical Use of Angiotensin I/II (1-5) in RAS Research Work

  2026-07-31

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled modeling of the renin-angiotensin system, specifically in studies of blood pressure regulation and aldosterone signaling. It is not suitable for research outside cardiovascular and renal signaling due to its mechanistic and solubility profile.

• Polyethylenimine Linear (PEI) MW 40,000: Optimizing DNA Tran

  2026-07-31

  Polyethylenimine Linear (PEI), MW 40,000, stands out as a versatile DNA transfection reagent for in vitro studies, delivering robust and reproducible gene expression across a spectrum of cell lines and scales. This article details best-practice protocols, advanced use-cases, and troubleshooting strategies to help researchers maximize transfection efficiency and experimental throughput.

• SAR131675: Illuminating VEGFR-3 Inhibitor Utility in Hepatic

  2026-07-30

  Explore how SAR131675, a selective VEGFR-3 inhibitor, enables precise dissection of the VEGFC–VEGFR-3 axis in hepatic fibrosis and immune modulation. This analysis offers fresh insights distinct from standard angiogenesis workflows, guiding advanced research applications.

• RP3-340N1.2 Knockdown Limits NSCLC Growth via IL-6 mRNA Dest

  2026-07-30

  The reference study reveals that the lncRNA RP3-340N1.2 promotes non-small cell lung cancer (NSCLC) proliferation and migration by stabilizing IL-6 mRNA. Knockdown of RP3-340N1.2 enhances IL-6 mRNA degradation through increased interaction with ZC3H12A, suggesting a novel therapeutic avenue for disrupting tumor-promoting cytokine signaling in NSCLC.

• Synthetic mRNA-Induced DEFB1 Reduces Cryptosporidium Infecti

  2026-07-29

  This study demonstrates that transfection of human intestinal cells with synthetic DEFB1 mRNA markedly increases β-defensin 1 protein production, resulting in a substantial (~80%) reduction in Cryptosporidium parvum infection. The findings support mRNA-based host-directed therapy as a promising platform for combating enteric parasites, with implications for rapid functional genomics and therapeutic development.

15880 records 1/1059 page Next 12345 下5页 Last page